Table 5.
Comparison between the postoperative complete remission (-) tyrosine kinase inhibitors (+) and postoperative complete remission (-)tyrosine kinase inhibitors (-) groups
|
|
Category
|
POCR (-)/TKI (+)
|
POCR (-)/TKI (-)
|
P
value
|
| Age | < 60/≥ 60 | 4/2 | 7/9 | 0.6351 |
| Sex | Male/female | 6/0 | 15/1 | 1.0000 |
| HBV and/or HCV | -/ + | 2/4 | 4/12 | 1.0000 |
| Alb (g/dL) | < 3.7/≥ 3.7 | 1/5 | 9/7 | 0.1619 |
| T-Bil (mg/dL) | ≤ 0.8/> 0.8 | 4/2 | 9/7 | 1.0000 |
| PT (%) | < 90/≥ 90 | 2/4 | 7/9 | 1.0000 |
| ICGR15 (%) | < 15/≥ 15 | 4/2 | 10/6 | 1.0000 |
| AFP (ng/mL) | < 200/> 200 | 4/2 | 8/8 | 0.6462 |
| PIVKA-II | < 100/≥ 100 | 0/6 | 1/15 | 1.0000 |
| Child-pugh class | A/B | 6/0 | 13/3 | 0.5325 |
| Tumor size (cm) | < 10/≥ 10 | 4/2 | 6/10 | 0.3476 |
| Differentiation | Wel or mod/por | 4/2 | 8/8 | 0.6462 |
| pN | -/ + | 5/1 | 16/0 | 0.2727 |
| Macrovascular invasion | -/ + | 0/6 | 5/11 | 0.2663 |
| Distant metastasis | -/ + | 5/1 | 14/2 | 1.0000 |
| BCLC stage | B/C | 2/4 | 7/9 | 1.0000 |
| Anatomical hepatectomy | -/ + | 0/6 | 1/15 | 1.0000 |
| Number of tumors in the remnant liver | 1-3/≥ 4 | 0/6 | 5/11 | 0.2663 |
POCR: Postoperative complete remission; TKIs: Tyrosine kinase inhibitors; PT: Prothrombin time; ICGR15: Indocyanine green retention rate at 15 min; AFP: Alpha-fetoprotein; PIVKA-II: Protein induced by vitamin K absence/antagonist-II; BCLC: Barcelona Clinic Liver Cancer.